NLRP3 and Hyperglycemia: Considering the high prevalence of breast cancer in women with diabetes [29,30], we studied if hyperglycemia could exacerbate ipilimumab-induced cardiotoxicity and decreases its anticancer efficacy in human breast cancer cells (estrogen responsive and triple negative cells) and verified the involvement of NLRP3 and MyD88 in these processes.